ORIC Pharmaceuticals Inc (ORIC)
ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and Previously Treated NSCLC Patients with EGFR Atypical Mutations at the ESMO Asia Congress 2025
📈 **POSITIVE** • Medium confidence analysis (67%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (85%) **Content type:** Clinical